サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1565661

周期性発熱症候群市場：製品タイプ別、治療別、流通別、年齢層別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測

Periodic Fever Syndrome Market, By Product Type, By Treatment, By Distribution, By Age Group, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 301 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
周期性発熱症候群市場：製品タイプ別、治療別、流通別、年齢層別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年09月04日
発行: AnalystView Market Insights
ページ情報: 英文 301 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

周期性発熱症候群の市場規模は2023年に6億2,090万米ドルとなり、2024年から2032年にかけてCAGR 4.80%で拡大

周期性発熱症候群市場-市場力学

遺伝性疾患の有病率の増加が周期性発熱症候群のニーズを牽引

遺伝性疾患の有病率の増加が、周期性発熱症候群（PFS）のような疾患に対する効果的な治療に対する需要の増加を牽引しています。家族性地中海熱、高免疫グロブリンD症候群、TNF受容体関連周期性症候群（TRAPS）のような自己炎症性疾患に関連する遺伝子変異と診断される人が増えるにつれ、専門的な医療介入の必要性が高まっています。周期性発熱症候群は、繰り返す発熱と全身性の炎症を特徴とし、放置すれば患者のQOLに大きな影響を与えます。このような遺伝性疾患の増加により、医療従事者や研究者の間でPFSに対する意識が高まり、PFS特有の課題に対処するための高度な診断ツールや治療法が求められています。世界保健機関（WHO）によると、世界中で毎年推定24万人の新生児が先天性疾患により生後28日以内に死亡しています。また、先天性疾患により生後1ヶ月から5歳までの間に17万人の子供が死亡しています。そのため、製薬業界とバイオテクノロジー業界は、これらの疾患に関連する症状を管理・緩和する革新的な治療法の開発に取り組んでおり、患者の転帰を改善し、全体的な疾病負担を軽減することを目指しています。

周期性発熱症候群市場-主要インサイト

弊社リサーチアナリストの分析によると、世界市場は予測期間（2024-2032年）に約4.80%のCAGRで毎年成長すると予測されています。

製品タイプ別では、遺伝性周期性発熱症候群が2023年に最大の市場シェアを示すと予測されます。

治療セグメンテーションに基づくと、2023年には治療薬が主要タイプでした。

流通セグメント別では、病院薬局が2023年の主要タイプでした。

地域別では、北米が2023年に収益でリードしました。

周期性発熱症候群市場-セグメンテーション分析：

世界の周期性発熱症候群市場は、製品タイプ、治療、流通、年齢層、地域に基づいてセグメント化されます。

市場は製品タイプ別に2つに分類される：すなわち、遺伝性周期性発熱症候群と後天性周期性発熱症候群です。ヘルスケア専門家および患者の意識の高まりが、診断率の上昇につながっています。遺伝子検査を含む診断ツールの向上により、HPFSと同定される患者が増加しています。先進的な治療法、特にインターロイキン（IL）-1阻害剤（アナキンラやカナキヌマブなど）のような生物学的製剤の開発により、治療成績が向上しています。これらの革新的な治療は、より効果的な症状管理を提供し、より高い普及率につながっています。

市場は治療法に基づき4つのカテゴリーに分類される：薬物療法、遺伝子治療、対症療法、その他の新興治療です。遺伝子治療は、PFSの根本的な遺伝的原因に対処する標的治療の可能性を提供します。PFSの多くは特定の遺伝子変異によって引き起こされるため、遺伝子治療はこれらの変異を直接修正したり、関与する遺伝子の発現を調節したりすることができます。全体として、標的治療の可能性、技術の進歩、支援的な調査・規制環境の組み合わせが、周期性発熱症候群市場における遺伝子治療の高い市場シェアに寄与しています。

周期性発熱症候群市場-地理的洞察

北米の周期性発熱症候群市場は、希少遺伝子疾患に対する認識の高まり、診断ツールの進歩、治療選択肢の改善などを背景に著しい成長を遂げています。米国は、確立されたヘルスケアインフラ、大手製薬会社の存在、先進治療の恩恵を受ける患者数の増加により、市場を独占しています。カナダも、研究イニシアチブの拡大と希少疾患治療への投資の増加により、重要な役割を果たしています。米国食品医薬品局（FDA）とカナダ保健省の規制支援により、新しい治療法の承認が容易になり、同地域の市場成長がさらに加速しています。

周期性発熱症候群市場-競合情勢：

周期性発熱症候群（PFS）市場は、希少疾患やオーファンドラッグに注力する主要製薬企業の存在によって特徴付けられています。主要企業には、ノバルティス、Swedish Orphan Biovitrum（Sobi）、Regeneron Pharmaceuticalsなどがあります。ノバルティスは、生物学的製剤イラリス（カナキヌマブ）を通じて、クリオピリン関連周期性症候群（CAPS）を含む様々なPFSサブタイプを治療し、大きな市場シェアを占めています。免疫学と希少疾患治療に重点を置くソビもまた、キネレット（アナキンラ）という製品でPFSへの対応に重要な役割を果たしています。炎症性疾患治療で知られるリジェネロンはデュピクセント（デュピルマブ）を提供しており、PFS治療薬として検討可能です。市場は、ニッチな治療に焦点を当て、新規治療の研究開発を続ける小規模なバイオ医薬品企業によってさらに強化されています。競合は、技術革新、有効性、希少疾病用医薬品指定へのアクセスによって駆動され、この希少疾病市場のダイナミックな環境を作り出しています。

目次

第1章 周期性発熱症候群市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 周期性発熱症候群の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 周期性発熱症候群の産業研究

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 周期性発熱症候群市場： COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19後の影響分析

第6章 周期性発熱症候群の市場情勢

  • 周期性発熱症候群の市場シェア分析、2023年
  • 主要メーカー別内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 周期性発熱症候群市場- 製品タイプ別

  • 概要
    • セグメントシェア分析
    • 遺伝性周期熱症候群
      • 家族性地中海熱（FMF）
      • 高免疫グロブリン血症D症候群（HIDS）
      • 腫瘍壊死因子受容体関連周期性症候群（TRAPS）
    • 後天性周期熱症候群
      • 周期性発熱、アフタ性口内炎、咽頭炎、リンパ節炎（PFAPA）
      • その他の非遺伝性周期熱症候群

第8章 周期性発熱症候群市場- 治療別

  • 概要
    • セグメントシェア分析
    • 医薬品
    • 遺伝子治療
    • 治療
    • その他の新たな治療

第9章 周期性発熱症候群市場- 流通別

  • 概要
    • セグメントシェア分析
    • 病院薬局
    • 小売薬局
    • オンライン薬局
    • 専門クリニック

第10章 周期性発熱症候群市場- 年齢層別

  • 概要
    • セグメントシェア分析
    • 小児患者
    • 成人患者

第11章 周期性発熱症候群市場- 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析- 周期性発熱症候群業界

  • 競争ダッシュボード
  • 企業プロファイル
    • Novartis AG
    • Swedish Orphan Biovitrum AB（Sobi）
    • Regeneron Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Horizon Therapeutics plc
    • Takeda Pharmaceutical Company Ltd.
    • AbbVie Inc.
    • Eli Lilly and Company
    • Amgen Inc.
    • Sanofi SA
    • Others

第13章 アナリストの全方位展望

目次
Product Code: ANV3857

REPORT HIGHLIGHT

Periodic Fever Syndrome Market size was valued at USD 620.90 million in 2023, expanding at a CAGR of 4.80% from 2024 to 2032.

The Periodic Fever Syndrome market focuses on treatments for a group of rare autoinflammatory disorders characterized by recurrent episodes of fever and inflammation, including Familial Mediterranean Fever (FMF), TNF receptor-associated periodic syndrome (TRAPS), and Hyper-IgD syndrome (HIDS). The market is driven by advances in genetic research, which help in early diagnosis and personalized treatment options. Key therapeutic approaches include biologics, such as interleukin-1 inhibitors and TNF inhibitors, offering relief from symptoms and reducing flare-ups. Increased awareness among healthcare professionals and rising patient support initiatives also support market growth. Major players include Novartis, Sobi, and Pfizer, contributing to drug development and clinical trials aimed at addressing these disorders more effectively.

Periodic Fever Syndrome Market- Market Dynamics

Growing Prevalence of Genetic Disorders Leading the Need for Periodic Fever Syndrome

The growing prevalence of genetic disorders is driving an increased demand for effective treatments for conditions like Periodic Fever Syndrome (PFS). As more individuals are diagnosed with genetic mutations linked to autoinflammatory diseases, such as familial Mediterranean fever, hyperimmunoglobulin D syndrome, and TNF receptor-associated periodic syndrome (TRAPS), the need for specialized medical interventions has escalated. Periodic Fever Syndrome, characterized by recurrent fevers and systemic inflammation, can significantly impact patients' quality of life if left untreated. This rise in genetic disorder cases has heightened awareness among healthcare professionals and researchers, pushing for advanced diagnostic tools and therapies to address the unique challenges posed by PFS. According to the World Health Organization, an estimated 240,000 newborns die worldwide within 28 days of birth every year due to congenital disorders. Congenital disorders cause a further 170,000 deaths of children between the ages of 1 month and 5 years. Consequently, the pharmaceutical and biotechnology sectors are working towards developing innovative treatments to manage and alleviate the symptoms associated with these conditions, aiming to improve patient outcomes and reduce the overall disease burden.

Periodic Fever Syndrome Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.80% over the forecast period (2024-2032)

Based on product type segmentation, Hereditary Periodic Fever Syndromes was predicted to show maximum market share in the year 2023

Based on treatment segmentation, Medications was the leading type in 2023

Based on distribution segmentation, Hospital Pharmacies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Periodic Fever Syndrome Market- Segmentation Analysis:

The Global Periodic Fever Syndrome Market is segmented on the basis of Product Type, Treatment, Distribution, Age Group, and Region.

The market is divided into two categories based on product type: Hereditary Periodic Fever Syndromes, and Acquired Periodic Fever Syndromes. Increased awareness among healthcare professionals and patients has led to higher diagnosis rates. With better diagnostic tools, including genetic testing, more individuals are being identified with HPFS. The development of advanced therapeutic options, particularly biologics like interleukin (IL)-1 inhibitors (e.g., anakinra and canakinumab), has improved treatment outcomes. These innovative treatments offer more effective symptom management, leading to higher adoption.

The market is divided into four categories based on treatment: Medications, Gene Therapy, Symptomatic Treatment, and Other Emerging Therapies. Gene therapy offers the potential for targeted treatments that address the underlying genetic causes of PFS. Since many PFS conditions are caused by specific genetic mutations, gene therapy can directly correct these mutations or modulate the expression of the genes involved. Overall, the combination of targeted treatment potential, technological advancements and supportive research and regulatory environments contribute to the high market share of gene therapy in the Periodic Fever Syndrome market.

Periodic Fever Syndrome Market- Geographical Insights

The Periodic Fever Syndrome market in North America is experiencing notable growth, driven by an increasing awareness of rare genetic conditions, advancements in diagnostic tools, and improved treatment options. The United States dominates the market due to a well-established healthcare infrastructure, the presence of major pharmaceutical companies, and a growing patient population benefiting from advanced therapies. Canada also plays a key role, with expanding research initiatives and rising investment in rare disease treatments. Regulatory support from the U.S. Food and Drug Administration (FDA) and Health Canada has facilitated the approval of new treatments, further accelerating market growth in the region.

Periodic Fever Syndrome Market- Competitive Landscape:

The Periodic Fever Syndrome (PFS) market is characterized by the presence of key pharmaceutical companies focusing on rare diseases and orphan drugs. Major players include Novartis, Swedish Orphan Biovitrum (Sobi), and Regeneron Pharmaceuticals. Novartis, through its biologic therapy Ilaris (canakinumab), holds a significant market share by treating a variety of PFS subtypes, including Cryopyrin-Associated Periodic Syndromes (CAPS). Sobi, with its strong emphasis on immunology and rare disease therapies, also plays a crucial role in addressing PFS with its product Kineret (anakinra). Regeneron, known for its work in inflammatory diseases, offers Dupixent (dupilumab), which can be explored for PFS. The market is further bolstered by smaller biopharmaceutical companies focusing on niche treatments, with ongoing research and development for novel therapies. Competition is driven by innovation, efficacy, and access to orphan drug designations, creating a dynamic environment in this rare disease market.

Recent Developments:

In June 2020, Researchers at the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, discovered clues to the possible cause of recurring, non-contagious fevers and sores that affect only children. Several genes have been implicated with the syndrome, known as PFAPA syndrome which could lead to new treatments.

In September 2020, Novartis announced that the US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of Ilaris (canakinumab) to treat three rare and distinct types of Periodic Fever Syndromes.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PERIODIC FEVER SYNDROME MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Novartis AG
  • Swedish Orphan Biovitrum AB (Sobi)
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Horizon Therapeutics plc
  • Takeda Pharmaceutical Company Ltd.
  • AbbVie Inc.
  • Eli Lilly and Company
  • Amgen Inc.
  • Sanofi S.A.
  • Others

GLOBAL PERIODIC FEVER SYNDROME MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Hereditary Periodic Fever Syndromes
  • Familial Mediterranean Fever (FMF)
  • Hyperimmunoglobulinemia D Syndrome (HIDS)
  • Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS)
  • Acquired Periodic Fever Syndromes
  • Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA)
  • Other Non-Hereditary Periodic Fever Syndromes

GLOBAL PERIODIC FEVER SYNDROME MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Medications
  • Gene Therapy
  • Symptomatic Treatment
  • Other Emerging Therapies

GLOBAL PERIODIC FEVER SYNDROME MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics

GLOBAL PERIODIC FEVER SYNDROME MARKET, BY AGE GROUP - MARKET ANALYSIS, 2019 - 2032

  • Pediatric Patients
  • Adult Patients

GLOBAL PERIODIC FEVER SYNDROME MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Periodic Fever Syndrome Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Periodic Fever Syndrome Market Snippet by Product Type
    • 2.1.2. Periodic Fever Syndrome Market Snippet by Treatment
    • 2.1.3. Periodic Fever Syndrome Market Snippet by Distribution
    • 2.1.4. Periodic Fever Syndrome Market Snippet by Age Group
    • 2.1.5. Periodic Fever Syndrome Market Snippet by Country
    • 2.1.6. Periodic Fever Syndrome Market Snippet by Region
  • 2.2. Competitive Insights

3. Periodic Fever Syndrome Key Market Trends

  • 3.1. Periodic Fever Syndrome Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Periodic Fever Syndrome Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Periodic Fever Syndrome Market Opportunities
  • 3.4. Periodic Fever Syndrome Market Future Trends

4. Periodic Fever Syndrome Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Periodic Fever Syndrome Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Periodic Fever Syndrome Market Landscape

  • 6.1. Periodic Fever Syndrome Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Periodic Fever Syndrome Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2023 & 2032 (%)
    • 7.1.2. Hereditary Periodic Fever Syndromes
      • 7.1.2.1. Familial Mediterranean Fever (FMF)
      • 7.1.2.2. Hyperimmunoglobulinemia D Syndrome (HIDS)
      • 7.1.2.3. Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS)
    • 7.1.3. Acquired Periodic Fever Syndromes
      • 7.1.3.1. Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA)
      • 7.1.3.2. Other Non-Hereditary Periodic Fever Syndromes

8. Periodic Fever Syndrome Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 8.1.2. Medications
    • 8.1.3. Gene Therapy
    • 8.1.4. Symptomatic Treatment
    • 8.1.5. Other Emerging Therapies

9. Periodic Fever Syndrome Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies
    • 9.1.5. Specialty Clinics

10. Periodic Fever Syndrome Market - By Age Group

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 10.1.2. Pediatric Patients
    • 10.1.3. Adult Patients

11. Periodic Fever Syndrome Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Periodic Fever Syndrome Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Periodic Fever Syndrome Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Periodic Fever Syndrome Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Periodic Fever Syndrome Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Periodic Fever Syndrome Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Periodic Fever Syndrome Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Novartis AG
    • 12.2.2. Swedish Orphan Biovitrum AB (Sobi)
    • 12.2.3. Regeneron Pharmaceuticals, Inc.
    • 12.2.4. Pfizer Inc.
    • 12.2.5. Horizon Therapeutics plc
    • 12.2.6. Takeda Pharmaceutical Company Ltd.
    • 12.2.7. AbbVie Inc.
    • 12.2.8. Eli Lilly and Company
    • 12.2.9. Amgen Inc.
    • 12.2.10. Sanofi S.A.
    • 12.2.11. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us